Objective: The combination of D-dimer and Wells score can exclude, but not confirm, the diagnosis of deep venous thrombosis (DVT). Since thrombosis and inflammation are interrelated, we evaluated the combination of soluble P-selectin (sPsel) with other inflammatory biomarkers for the diagnosis of DVT. Methods: Sixty-two positive and one hundred and sixteen patients with negative DVT, by duplex scan, were prospectively evaluated for sPsel, D-dimer, C-reactive protein (CRP), microparticles (MPs; total, leukocyte, and platelet-derived and tissue factor positive microparticles), and clinical Wells score. Results: Biomarkers and clinical scores that differentiated DVT positives from negatives were sPsel (87.3 vs 53.4 ng/mL, P < .0001), D-dimer (5.8 vs 2.1 mg/ L, P < .0001), CRP (2.1 vs 0.8 mg/mL, P < .0005), and Wells score (3.2 vs 2.0, P < .0001). For MP analysis, platelet-derived MPs were found to differentiate DVT from negatives. Using multivariable logistic regression, a combination of sPsel and Wells score could establish the diagnosis of DVT (cut point !90 ng/mL þ Wells !2), with a specificity of 96% and positive predictive value (PPV) of 100%, and could exclude DVT diagnosis (cut point 60 ng/mL and Wells <2) with a sensitivity of 99%, a specificity of 33%, and a negative predictive value (NPV) of 96%. Conclusion: This study establishes a biomarker and clinical profile combination that can both confirm and exclude the diagnosis of DVT.
Introduction
Venous thromboembolism (VTE) remains a significant health problem in the United States with an estimated 900 000 cases of deep venous thrombosis (DVT) and pulmonary embolism (PE) occurring yearly. 1 Timely and accurate diagnosis of DVT is often difficult due to the diffuse symptoms a patient may manifest. Currently, scoring systems based on a patient's presentation are used to establish the probability of having a venous thrombosis and to determine if further diagnostic testing is warranted. 2 In the majority of cases, diagnosis is based on confirmatory compression duplex ultrasound. However, ultrasound is not always available. Use of plasma D-dimer testing has proved successful in excluding the presence of venous thrombosis. [2] [3] [4] However, there is no current biomarker or combination of biomarkers and clinical presentation that can confirm the diagnosis, when ultrasound is unavailable.
In 1970s, Gwendolyn J. Stewart suggested a relationship between inflammation and thrombosis. 5 P-selectin, a protein from the lectin family and a cell adhesion molecule, is the first upregulated glycoprotein on activated endothelial cells and platelets and has procoagulant properties. P-selectin, stored in the platelets (alpha granules) and in the endothelial cells (Weibel-Palade bodies), is translocated to the cell surface after activation and partially released into the circulation in its soluble form. The binding of P-selectin to its specific counter receptor, P-selectin-specific ligand-1 (PSGL-1, present on the surface of leukocytes and platelets), initiates various procoagulant mechanisms. 6 This binding also initiates the signaling that mediates leukocyte-endothelial cell, leukocyte-platelet, leukocyte-leukocyte, and platelet-endothelial cell interactions. 3 This interaction, P-selectin with PSGL-1, also releases procoagulant microparticle (MP) which carry tissue factor (TF), the initial trigger for thrombogenesis and other procoagulant factors. Moreover, P-selectin induces both the exposure of phosphatidylserine and up-regulation of TF on monocytes, modulating the initial thrombus amplification. 7 Several studies, despite the small sample size, have demonstrated elevated levels of soluble P-selectin (sPsel) in patients with DVT. [8] [9] [10] [11] [12] [13] In addition, a decrease in plasma sPsel levels, after 7 days of therapeutic heparin therapy, have also been demonstrated. 14 Lastly, P-selectin has been found to be intimately associated with venous thrombogenesis experimentally. 15 Inhibiting P-selectin causes an increase in thrombus regression [15] [16] [17] and vein recanalization and a decrease in thrombus formation and vein wall fibrosis. 15 Microparticles are small fragments of cell membranes shed from platelets, leukocytes, and endothelial cells. They are rich in TF and other procoagulant factors that facilitate and magnify coagulation in the presence of thrombus. 18, 19 Recent studies have investigated the role of procoagulant MP formation in regards to the inflammatory component of venous thrombosis. 3, 16, [20] [21] [22] We previously performed a pilot study which demonstrated that a combination of MP analysis, sPsel and D-dimer levels produced sensitivity and specificity rates of, respectively, 73% and 81% for the diagnosis of DVT. 23 The best sensitivity and specificity (94% and 94%, respectively, for proximal thrombosis) for the diagnosis of DVT is still B-mode compression ultrasound with or without color. 24 However, ultrasound is not always available when needed to make the diagnosis of DVT. In order to improve sensitivity and specificity of inflammatory markers and clinical characteristics, we evaluated a number of inflammatory biomarkers and clinical characteristics in a larger population of patients.
Methods

Patients and Inclusion Criteria
The University of Michigan Institutional Review Board approved this protocol. All patients signed written informed consent prior to enrollment. This study included participants that were older than 18 years, any gender or ethnicity, and positive for acute DVT, as confirmed by duplex scan (n ¼ 62). For MP analysis, patients with leg pain, but negative for deep vein thrombosis, by duplex scan, were also enrolled (n ¼ 116) along with healthy controls (n ¼ 30). Exclusion criteria included participants younger than 18 years, unwilling to consent, actively pregnant, or on immunosuppressant or anticoagulant therapy. Patients with isolated calf venous thrombosis were also excluded.
Patient Stratification
From January 2006 to October 2009, patients were screened through the University of Michigan Diagnostic Vascular Unit. Controls were recruited randomly and interviewed in order to determine their current health conditions and medical status. Controls were used for fold change calculations, and comparisons were made between patients positive versus negative, for DVT. In addition, patient demographics and clinical characteristics, including the Wells scores, were recorded, along with all risk factors associated with venous thrombosis. The Wells score considers 1 point each for active cancer, paralysis, paresis, recent plaster immobilization of lower limb, recently bedridden for >3 days, or major surgery in past 4 weeks; localized tenderness along the distribution of deep venous system; entire leg swollen; calf swelling >3 cm compared to asymptomatic leg; pitting edema and collateral superficial veins. The score subtracts 2 points for alternative diagnoses as likely as, or more likely than, DVT. A Wells score of 0 or 1 is associated with a low probability of venous thrombosis, a score of 2 with an intermediate probability of DVT and scores greater than 3 with a high probability of venous thrombosis. 2 Normal Controls Inclusion Criteria. Normal controls had to be older than 18 years, with no signs or symptoms of either active or previous history of DVT, active pregnancy, or having no acute or chronic medical condition. Healthy controls also submitted to a duplex scan (upper and lower limbs) evaluation.
Sample Processing
At the time of enrollment/consent, blood samples were collected (2.75 mL in 3% sodium citrate tubes and 8.5 mL in 10% acid citrate dextrose tubes). In patients positive for DVT, blood was obtained before anticoagulant therapy was initiated. Sodium citrate tubes were spun for 10 minutes, at 4 C, 2000g. The plasma was then drawn off, aliquotted out, snap frozen in liquid nitrogen, and stored at À70 C for enzyme-linked immunosorbent assay (ELISA) measurements. Acid citrate dextrose tubes were spun at room temperature at 1500g for 25 minutes. The clear plasma was spun again at 15 000g for 2 minutes at room temperature in order to remove contaminating cells. The plasma was removed, put into 1-mL aliquots, snap frozen in liquid nitrogen and stored at À70 C for MP analysis.
Soluble P-Selectin, E-Selectin, D-Dimer, and C-Reactive Protein Analysis
Enzyme-linked immunosorbent assays were used to evaluate circulating sPsel, soluble E-selectin (R&D Systems Inc, Minneapolis, Minnesota), D-dimer (Hyphen Biomed, Neuvillesur-Olse, France), C-reactive protein (CRP; US Biological, Swampscott, Massachusetts), and were reported in ng/mL (sPsel, E-selectin), mg/mL (CRP), and mg/L (D-dimer). Samples prepared according to manufacturer's instructions were run in duplicate, and plates were read on an Elx808 plate reader (Biotek, Vermont) at 450 nm wavelength. Results were normalized to total protein using the bicinchoninic acid (BCA) assay (Pierce Rockford, Illinois) and reported as ng/mg total protein (ng/mg TP). This analysis was performed in a blinded fashion. 23 
Microparticle Analysis
For total MP, MP derived from leukocytes and platelets, and TF-bound MP analysis, platelet poor plasma was centrifuged for 2 hours at 200 000g to separate the MPs. The supernatant was then removed, and the pelleted MPs were resuspended in HEPES buffer (pH 7.4). Antibodies that stain leukocytes, platelets, and TF were added to the samples included; anti-FITC CD11b (leukocytes) 10 mL/test (AbD Serotec Raleigh, North Carolina), anti-Cy5 CD41 (platelets) 15 mL/test (Biolegend San Diego, California), and anti-PE DC142 (TF) 20 mL/test (BD Pharmingen, San Diego, California). Unstained MPs were used as the negative control. Antibody binding beads (Pharmingen, San Diego, California) were used as positive controls for fluorochromes. Samples were centrifuged for 2 hours at 200 000g, washed with phosphate buffered saline, fixed with 0.5% paraformaldehyde, and stored at 4 C for fluorescence activated cell sorter (FACS) analysis. To count the total MP population, 25 mL of SPHERO Rainbow calibration 3.4-mm beads (approximately 250 000 beads) were added to tubes prior to FACS. Five thousand bead events were counted and the total MPs determined by multiplying the MP events by 50. Samples were run on a Becton Dickinson Facscalibur System and analyzed using CellQuest software (BD Pharmingen). Tissue factor positive MPs were also analyzed by ELISA methods (R&D Systems Inc).
Cut Points
D-Dimer and CRP cut points were based on manufacturer recommendations of normal versus abnormal values. Microparticle cut points were based on fold changes, compared to controls, as described in our previous study. 23 The sPsel cut point was determined on the sensitivity/specificity curve comparing patients with positive venous thrombosis versus patients with negative venous thrombosis, using regressive multivariable logistic analysis. No cut point was selected for E-selectin due to the equivalent values of both groups. Cut point values are presented in Table 1 .
Statistical Analysis
Dichotomous and continuous data were analyzed using multiple logistic regression, Student t test, Mann-Whitney rank sum test, and chi-square tests, where appropriate. Significance was set with an a ¼ 5% with P .05. t Tests and Wilcoxon rank sum tests were used to assess group differences for continuous measurements. Logistic regression models were used to study various independent variables (alone and in combination) as pertaining to their relationship to venous thrombosis. These models produced estimates of sensitivity and specificity for various cut points. These estimates were adjusted to reduce the bias incurred from using the same cases to estimate both the statistical model and the sensitivity/specificity values. Receiver operating characteristic (ROC) curves were constructed using the sensitivity versus 1-specificity to assess the diagnostic value of 2 biomarkers combined or a biomarker combined with the Wells score. To create positive and negative predictive values estimation, we computed a logistic regression model with one or more independent variables. From these models, we calculated the model estimate of the probability of venous thrombosis for specific values of the independent variable (or variables) which we thought would provide good discrimination. We then calculated the model estimates of the probability of DVT for each case used in the logistic regression. For each cut point (eg, cut point 90 ng/mL for sPsel), we created a dichotomous variable for all cases in our data set by comparing the probability of venous thrombosis for each case to the probability of DVT, associated with the selected cut point. We then built a 2 Â 2 contingency table which identified the number of positive and negative cases that were correctly or incorrectly classified. From the 4 numbers in each such table, we estimated positive and negative predictive scores associated with the cut point.
As needed, comparisons were adjusted for body mass index (BMI) in the regressive model. We defined the optimal biomarker, either alone or in combination, as that presenting the best combination of receiver operating characteristic, sensitivity, specificity, negative (NPV) and positive predictive values (PPV), and P value.
Results
Demographics and Risk Factors for Venous Thrombosis. Three hundred and eighteen participants made up this study, with 208 eligible for analysis. Sixty-two (32 males, 30 females) were confirmed positive for DVT as documented by compression ultrasound, 116 (47 males, 69 females) presented with leg pain but were negative for DVT by duplex scan, and 30 (12 males, 18 females) were healthy controls without any Table 2 .
Soluble P-Selectin. Using a logistic regression model, sPsel alone presented a receiver operating characteristic curve (ROC) area of 0.76 (P < .0001) was 28% sensitive and 96% specific at the cut point 90 ng/mL. Patients with cancer (n ¼ 33 positive for DVT, 27 negative) presented with higher levels of sPsel (active cancer ¼ 78.9 + 50 ng/mL, previous cancer ¼ 82.6 + 33 ng/ mL). Exclusion of patients with cancer did not significantly impact the sensitivity/specificity of sPsel (Table 3) .
Soluble P-Selectin and Wells Score. Adding the Wells score to sPsel improved the results. The ROC area for the combination of sPsel and the Wells score was 79% (P < .0001). The multivariable logistic regression analysis showed that a combination of sPsel and the Wells score (cut point of 90 ng/mL or above and Wells score !2) was 33% sensitive and 95% specific to establish the diagnosis of DVT with a PPV of 100%. The use of cut point 60 ng/mL and Wells score <2 could rule out the diagnosis of DVT with a sensitivity of 99%, specificity of 33%, and a NPV of 96% (Table 4 ).
D-Dimer. D-Dimer alone presented a ROC area of 83%, was 98% sensitive and 29% specific, with a NPV of 80% and a PPV of 40% (Table 4 ). D-Dimer and Wells Score. The ROC area for the combination of D-dimer and Wells score in the multivariable logistic regression was 84%. This combination was 93% sensitive and 45% specific (P < .0001), with a NPV of 81% and a PPV of 44% (Table 4 ).
Soluble P-Selectin and D-Dimer. The ROC area for the combination of sPsel and D-dimer was 83% (P < .0001). The logistic regressive multivariable analysis showed that this combination (cut points 90 ng/mL for sPsel and 0.5 mg/L for D-dimer) was 43% sensitive and 81% specific, with a NPV of 81% and a PPV of 58% (Table 4 ).
C-Reactive Protein. C-reactive protein also discriminated DVT positives from negatives (2.2 vs 0.8 mg/mL, P < .0005).
The P value observed with CRP was lower than that observed with sPsel and D-dimer ( Table 2 ). The standard deviation was also high (SD ¼ +3.4) and even combining it with the Wells score or other biomarkers did not increase the sensitivity/ specificity.
Microparticles. Total, leukocyte-derived, and TF-bound MP did not discriminate patients positive for DVT from the patients negative for DVT. Platelet-derived MP discriminated those positive for DVT from negatives (1.4 + 2.1-fold change vs 0.8 + 0.9-fold change, P ¼ .04, Table 2 ). The association with Wells score or other biomarkers did not increase the sensitivity/specificity, when compared with the previously reported biomarkers.
In patients, the best overall combination for the prediction of positive DVT versus negative was sPsel plus the Wells score. Using this combination, with 2 different cut points, 42 patients negative for DVT presented with a sPsel 60 ng/mL and a Wells score <2, while 14 positives had a sPsel !90 ng/mL and a Wells score !2. Thus, using the current dataset, 32% (56/178) could potentially be diagnosed with DVT without the need of imaging exams, when such imaging is not available.
Discussion
The most commonly used clinical marker for VTE is D-dimer. A negative value of D-dimer may safely rule out both DVT and PE, with a high sensitivity up to 95%. 2 It has also been proven to be useful to guide oral anticoagulation withdrawal. High levels of D-dimer indicate states of hypercoagulability and correlate to a higher risk of VTE recurrence. [25] [26] [27] [28] However, due to its low specificity (around 40%), D-dimer, even combined with clinical criteria, cannot be used to diagnose the DVT. For example, a higher value of D-dimer is not necessarily correlated to the presence of a VTE. Its value also increases with recent surgery, trauma, or infection. Elevated levels are also seen with liver disease, pregnancy, and renal disease. 29 There is evidence that sPsel and other mediators involved in inflammation are increased with venous thrombosis. Smith et al demonstrated in 1999, a correlation between venous thrombosis and an increase in sPsel levels. 30 Ay et al reported the association of elevated sPsel with VTE in their study comparing 116 patients with recurrent VTE to 129 controls, with an OR of 10.6 (95% CI: 3.7 to 23.3). 9 The same group reported a correlation between high levels of sPsel and a risk of VTE in 687 prospectively studied patients with cancer. 10 Recently, Li Wang and collaborators, prospectively evaluating sPsel and D-dimer for the diagnosis of postoperative splenic or portal vein thrombosis, demonstrated that the ROC curves of D-dimer and sPsel showed a significant PPV in patients with thrombosis. Interestingly, sPsel with a cut point of 90 ng/mL, the same used in our study, led to 85.2% sensitivity and 85.5% specificity for establishing the diagnosis of thrombosis. The combination of sPsel and D-dimer yielded a 82% sensitivity and 98% specificity. 31 Our previous pilot study, evaluating 75 patients, demonstrated a sensitivity of 73% and a specificity of 81% combining sPsel with total MP and D-dimer. 23 In the present study, involving a larger sample number, sPsel alone was a better biomarker than D-dimer. The criteria for the best combination of biomarkers included the area under the ROC curve, a combination of P value for the regression coefficient, sensitivity and specificity for the chosen cut points, as well as the PPV and NPV values. Soluble P-selectin, when combined with the Wells score presented the best combination. With a suspicion of DVT, a high Wells score (!2) and sPsel above 90 ng/mL could establish for the first time the diagnosis of DVT, with a PPV value of 100%. Interestingly, using the cut point 60 ng/mL or below and Wells score <2 could also exclude the diagnosis of DVT, with a NPV value of 96%, similar to the reported NPV value for D-dimer and Wells score. 2 Using the combination of sPsel and Wells score could potentially decrease the number of confirmatory imaging exams needed by 32% of patients with suspicion of DVT in the situation when ultrasound is not available. The combination of sPsel (90 ng/mL) and D-dimer (0.5 mg/L) yielded a high area under the ROC curve (83%), with a specificity of 81%. However, this combination decreased the sensitivity for the diagnosis to 43%. The PPV and NPV for the combination of sPsel and D-dimer did not achieve the values of sPsel combined with the Wells score, the best combination in this study.
Microparticle analysis in general did not discriminate positives from negatives in the present study. The only subgroup of MP that identified a difference between positive and negative patients was platelet-derived MP. However, the number of MP analyses run was smaller than the ELISA-tested biomarkers to date, leading to a high standard deviation (1.4 + 2.1-fold change). Out of the 208 analyzed patients, only 44 positives and 58 negatives were submitted to MP analysis. A larger sample size will better clarify MP role as biomarkers for VTE.
There are several weakness in this study. First the small number of inpatients (7%) do not allow conclusions to be made about the usefulness of these cut points in an inpatient setting. Inpatient studies, including stratification of risk of DVT in the intensive care unit are currently underway. Second, we have pooled a small sample of patients with cancer (60/178, 34%), populations that already have high levels of baseline sPsel. A separate study including only the patients with cancer is being developed. Finally, it is always problematic to use the same dataset to both define the statistical model and determine sensitivity and specificity. The next step is to run a validation study of the cut points determined in this current study. The strengths of the current study include its prospective nature, patient recruitment from a single institution, and a ratio of positive/negative patients of 1:2, reflecting the reality of patients presenting with leg pain at our institution. This ratio allowed the analysis of PPV and NPV values. Moreover, the regressive multivariable analysis provided normalization for the body mass index, and the P values were strongly significant for the biomarkers analyzed.
Conclusions
Soluble P-selectin has a high specificity (95%) and can establish the diagnosis of DVT with a cut point of 90 ng/mL, when combined with the Wells score !2, with a PPV of 100%. Soluble P-selectin has a high sensitivity (99%), and can exclude the diagnosis of DVT with cut points below 60 ng/mL, when combined with the Wells score <2, with a NPV of 96%. Based on our data, 32% (56/178) of patients could potentially be diagnosed with DVT without the need of imaging exams. Biomarkers today are still not as accurate as the gold standard of compression ultrasound for the diagnosis of DVT but might be accurate enough to establish or exclude the diagnosis for some patients when ultrasound is unavailable.
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